Financial Releases - July 27, 1995

Lexington, Massachusetts, July 27, 1995 -- AutoImmune Inc. (Nasdaq: AIMM) today reported a net loss of $4.7 million, or $.38 per share, for the quarter ended June 30, 1995, compared with a net loss of $3.5 million or $.34 per share, for the same quarter a year earlier. This brings the net loss for the first six months of 1995 to $8.5 million, or $.71 per share, compared to a net loss of $6.3 million, or $.61 per share, for the same period in 1994.

Research and development expenses increased to $7.9 million for the first half of 1995, from $5.8 million in the comparable 1994 period, primarily due to expanding human clinical development programs for Myloral^TM and Colloral^TM.

AutoImmune Inc. is a biopharmaceutical company developing a new class of drug therapies for the treatment of autoimmune diseases. With highly focused use of its human and capital resources, the Company has successfully brought four product candidates based on the principle of oral tolerance into human clinical testing. These orally administered products are targeted for the treatment of multiple sclerosis, rheumatoid arthritis, autoimmune-mediated diabetes and uveitis.

R e t u r n